Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Phase 4

BonE and Joint Infections - Simplifying Treatment in Children Trial

NCT04538053 · tracked via the Priya Life Science Ireland tracker
Phase
Phase 4
Started
2021-06-01
Last updated
2026-10-27

Condition(s) studied

Bone InfectionSeptic ArthritisBone and Joint InfectionOsteomyelitis

Investigational drug(s) / intervention(s)

Oral cefalexin onlyIV cefazolin or IV flucloxacillin followed by oral cefalexin →

Oral cefalexin only: High-dose oral cefalexin

IV cefazolin or IV flucloxacillin followed by oral cefalexin: Standard therapy of IV cefazolin or IV flucloxacillin followed by high dose oral cefalexin

Study summary

This is a multi- centre trial of children with bone and joint infections (BJIs) at eleven major paediatric hospitals in Australia, New Zealand and Ireland. The primary objective is to establish if in children with acute, uncomplicated BJIs, entirely oral antibiotic treatment is not inferior to initial intravenous (IV) treatment for 1 to 7 days followed by an oral antibiotic course in achieving full recovery 3 months after presentation. Children will be randomly allocated to the 'entirely oral antibiotic' group or the 'standard treatment' group.

Eligibility

Sex
ALL
Min age
1 Year
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: 1. Children aged 1 to 18 years with acute, uncomplicated, uncomplicated, haematogenous osteomyelitis or septic arthritis 2. Symptoms are present for ≤10 days 3. Osteomyelitis (OM): involvement of long bones of arm or leg AND either pain, point tenderness upon palpation of bone or joint, or difficulty weight bearing; OR Septic arthritis (SA): any of painful and/or swollen large joint; restriction of joint movement; tenderness or warmth. Those with both SA and OM at the same site as the current infection are also eligible. 4. The participant has an elevated C-reactive protein (CRP) ≥20 mg/L or erythrocyte sedimentation rate (ESR) ≥10 mm/h Exclusion Criteria: 1. Infection due to bacteria resistant to cefalexin or atypical infection (e.g. mycobacterial, fungal) 2. Features of sepsis as defined by the presence of organ dysfunction (defined using definitions within the Pediatric Logistic Organ Dysfunction-2 (PELOD-2) score) 3. Concomitant severe, invasive infection e.g. necrotising fasciitis 4. Complicated infection (e.g. presence of prosthetic material; large subperiosteal or intraosseous (either \>3 mm) abscess or soft tissue abscess without surgical intervention; infection secondary to or complicated by trauma) 5. History of allergy to cephalosporin antibiotics or immediate, severe reaction to penicillins 6. Received more than four IV or oral doses of an antibiotic with activity against the likely bacteria causing the current infection 7. Prior episode of osteomyelitis (OM) or septic arthritis (SA) of the same site 8. Prior condition predisposing to poor absorption (e.g. inflammatory bowel disease, current gastrointestinal symptoms) or complicated disease (e.g. immunodeficiency) 9. Prior enrolment in the trial 10. Current recipient of another investigational product as part of a clinical trial

Primary outcome measure(s)

  • Proportion of children assessed as having made a full recovery 3 months after presentation by an independent committee — 3 months
    Full recovery is defined by the absence of: (i) Clinical features of osteomyelitis or septic arthritis (ii) No episodes of disease recurrence (symptoms and signs of infection at the same site) requiring further antibiotic administration after cessation of initial treatment. Children will be assessed by an independent specialist paediatrician. The independent committee will include an orthopaedic surgeon, general paediatrician and infectious diseases physician, who will review the patient record and will be blinded to the initial trial assignment.

Trial sites (11)

FacilityCityRegionStatus
Nepean Hospital Kingswood New South Wales Recruiting
John Hunter Children's Hospital New Lambton Heights New South Wales Recruiting
Sydney Children's Hospital Network Sydney New South Wales Recruiting
The Children's Hospital at Westmead Sydney New South Wales Active Not Recruiting
Royal Darwin Hospital Darwin Northern Territory Recruiting
Queensland Children's Hospital Brisbane Queensland Recruiting
Women's and Children's Hospital Adelaide South Australia Recruiting
The Royal Children's Hospital Melbourne Victoria Recruiting
Perth Children's Hospital Perth Washington Recruiting
Children's Health Ireland Dublin Ireland Not Yet Recruiting
Christchurch Hospital Christchurch New Zealand Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04538053 on ClinicalTrials.gov ↗ ← All trials in Ireland